

Dr. Bruce E. Maryanoff A Tribute



This special issue of ARKIVOC is dedicated to Cynthia A. and Bruce E. Maryanoff to mark their distinguished careers in the pharmaceutical industry and their contributions to organic and medicinal chemistry.

Dr. Bruce E. Maryanoff was born on 26 February 1947 in Philadelphia, Pennsylvania. While growing up in Philadelphia, he established his first “laboratory” in the basement of his home at eight years of age. His chemistry education was formalized at Drexel University, where he earned a B.S. degree in chemistry (1969) and a Ph.D. degree in organic chemistry (1972; with Prof. Robert O. Hutchins). In 1971, he married Dr. Cynthia A. Maryanoff, an organic chemistry labmate. After postdoctoral studies for two years at Princeton University with Prof. Kurt M. Mislow, he joined McNeil Laboratories, Inc., a Johnson & Johnson subsidiary. He advanced on the scientific ladder in various Johnson & Johnson pharmaceutical units to the highest scientific position in the company. Presently, he is a Distinguished Research Fellow and a Team Leader in Johnson & Johnson Pharmaceutical Research & Development, Spring House, Pennsylvania.

Dr. Maryanoff has made numerous contributions to medicinal and organic chemistry. He is an internationally renowned expert in drug design and drug discovery. From 1976–1992, he focused on central nervous system (CNS) therapeutics, with an emphasis on anticonvulsants and

antidepressants. Dr. Maryanoff invented TOPAMAX® topiramate, a unique sugar sulfamate derivative, which is marketed worldwide for treating epilepsy and migraine headache, and achieved annual sales of more than \$2 billion. Since 1991, he has pursued cardiovascular therapeutics, while also seeking drugs for treating pulmonary inflammatory diseases, metabolic disorders, and epilepsy. In the past 15 years, his drug research has dealt with structure-based drug design; peptides and peptidomimetics; inhibitors of diverse enzymes, especially serine proteases (thrombin, factor Xa, tryptase, cathepsin G, chymase) and kinases (protein kinase C- β , glycogen synthase kinase-3 β); integrin (GPIIb/IIIa, α V β 3/5, α 4 β 1/7) antagonists; and ligands for G-protein-coupled receptors (protease-activated receptors, urotensin-II receptor, vasopressin receptors, ADP receptor P2Y₁₂). His efforts have led to 23 compounds entering preclinical development, 13 of which advanced into human clinical trials. In organic chemistry, he made seminal contributions to the understanding the stereochemistry and mechanism of the Wittig olefination reaction; adapted cobalt-mediated [2+2+2] alkyne cyclotrimerizations to the synthesis of macrocycles; and devised novel, self-assembling collagen-mimetic peptides. Dr. Maryanoff has published 265 scientific papers, is an inventor on 100 U.S. Patents (issued or pending), has presented 170 invited lectures, and has mentored 11 postdoctoral associates.

Throughout his tenure at Johnson & Johnson, Bruce has maintained a focus on developing his research group and postdoctoral scientists. His mentorship was less visible than that of a university professor, because his tutelage was performed inside the walls of a pharmaceutical company. However, his consistent application of scientific rigor and imagination produced an exceptionally mature ensemble of scientists, which provided the foundation for an impressive body of scientific accomplishment. He was a scientifically demanding mentor, yet supportive, resulting in a positive environment to grow. We became better scientists, communicators, and mentors through his leadership. He encouraged us to develop independent research programs and gave us great latitude in managing the day-to-day operations of our projects. When we encountered obstacles in the development of drug candidates, Bruce supported our efforts to build a stronger case for their recommendation. He knew from his own experience with TOPAMAX® that every path to a new drug meets resistance.

Bruce applies the same enthusiasm, perfectionism, and artistry to his personal pursuits, which include dining at the best restaurants of the world, cooking his own creations, enjoying fine wines, architectural design, gardening, flower arranging, and music.

Dr. Maryanoff has received two ACS national awards, a 2000 ACS Heroes of Chemistry Award and the 2003 ACS Award in Industrial Chemistry. The ACS Medicinal Chemistry Division inducted him into the Hall of Fame in 2008 and granted him the prestigious Edward E. Smisman Award in 2009. Dr. Maryanoff received a Philadelphia ACS Section Award (1984) and a Philadelphia Organic Chemists' Club Award (1995). He was honored with the Johnson Medal for Research and Development for discovery and development of TOPAMAX®, and was twice a recipient of Johnson & Johnson's Philip B. Hofmann Research Scientist Award. Dr. Maryanoff was recognized by Drexel University as a notable alumnus with several awards, including election to the Drexel Alumni 100 Club. He was elected a Fellow of the American

Association for the Advancement of Science (1989), a Fellow of the Royal Society of Chemistry (2000), and a Fellow of the ACS (2009; inaugural class).

Dr. William A. Kinney

IteraMed Consulting, Pennsylvania Biotechnology Center, Doylestown, PA, USA

E-mail: wkinney@iteramed.com

Joint Bibliography (Bruce and Cynthia Maryanoff)

1. The reaction of amines with methylene chloride. Evidence for rapid amination from *N*-methylenepyrrolidinium chloride and pyrrolidine. Mills, J. E.; Maryanoff, C. A.; McComsey, D. F.; Stanzione, R. C.; Scott, L. *J. Org. Chem.* **1987**, *52*, 1857.
2. The Wittig olefination reaction and modifications involving phosphoryl-stabilized carbanions. Stereochemistry, mechanism, and selected synthetic aspects. Maryanoff, B. E.; Reitz, A. B. *Chem. Rev.* **1989**, *89*, 863.
3. Mechanistic aspects of the ligand-assisted nucleophilic addition reaction. Swiss, K. A.; Liotta, D. C.; Maryanoff, C. A. *J. Am. Chem. Soc.* **1990**, *112*, 9393.
4. Asymmetric induction in an enammonium-iminium rearrangement. Mechanistic insight via NMR, deuterium labeling, and reaction rate studies. Application to the stereoselective synthesis of pyrroloisoquinoline antidepressants. Sorgi, K. L.; Maryanoff, C. A.; McComsey, D. F.; Graden, D. W.; Maryanoff, B. E. *J. Am. Chem. Soc.* **1990**, *112*, 3567.
5. Macrocyclic peptide inhibitors of serine proteases. Convergent total synthesis of cyclotheonamides A and B via a late-stage primary amine intermediate. Study of thrombin inhibition under diverse conditions. Maryanoff, B. E.; Greco, M. N.; Zhang, H.-C.; Andrade-Gordon, P.; Kauffman, J. A.; Nicolaou, K. C.; Liu, A.; Brungs, P. H. *J. Am. Chem. Soc.* **1995**, *117*, 1225.
6. Reductive aminations of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures. Abdel-Magid, A. F.; Carson, K. G.; Harris, B. D.; Maryanoff, C. A.; Shah, R. D. *J. Org. Chem.* **1996**, *61*, 3849.
7. Chemical process synthesis of β -amino acids and esters. Abdel-Magid, A. F.; Cohen, J. H.; Maryanoff, C. A. *Curr. Med. Chem.* **1999**, *6*, 955.
8. Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308. Hoekstra, W. J.; Maryanoff, B. E.; Damiano, B. P.; Andrade-Gordon, P.; Costanzo, M. J.; Haertlein, B. J.; Harris, B. D.; Hecker, L. R.; Hulshizer, B. L.; Kauffman, J. A.; Keane, P. M.; McComsey, D. F.; Mitchell, J. A.; Scott, L.; Yabut, S. B. *J. Med. Chem.* **1999**, *42*, 5254.
9. Synthesis of pyridine-containing macrocycles by cobalt-mediated trimerization of triply-bonded species. Moretto, A. F.; Zhang, H.-C.; Maryanoff, B. E. *J. Am. Chem. Soc.* **2001**, *123*, 3157.

10. Structure-function analysis of Urotensin II and its use in the construction of a ligand-receptor working model. Kinney, W. A.; Almond, H. R.; Qi, Jr. J.; Smith, C. E.; Santulli, R. J.; Garavilla, L. de; Andrade-Gordon, P.; Cho, D. S.; Everson, A. M.; Feinstein, M. A.; Leung, P. A.; Maryanoff, B. E. *Angew. Chem., Int. Ed.* **2002**, *41*, 2940.
11. Discovery of potent peptide-mimetic antagonists for the human thrombin receptor, protease-activated receptor 1 (PAR-1). Maryanoff, B. E.; Zhang, H.-C.; Andrade-Gordon, P.; Derian, C. K. *Curr. Med. Chem.-Cardiovasc. Hematol. Agents* **2003**, *1*, 13.
12. Inhibitors of serine proteases as potential therapeutic agents: the road from thrombin to trypsin to cathepsin G. Maryanoff, B. E. *J. Med. Chem.* **2004**, *47*, 769.
13. Cyclizations of *N*-acyliminium ions. Maryanoff, B. E.; Zhang, H.-C.; Cohen, J. H.; Turchi, I. J.; Maryanoff, C. A. *Chem. Rev.* **2004**, *104*, 1431.
14. Solution phase synthesis of the pulmonary surfactant KL-4, a 21 amino acid synthetic protein. Abdel-Magid, A.; Bos, M. E.; Eggmann, U.; Maryanoff, C. A.; Scott, L.; Thaler, A.; Villani, Jr. F. J. In *Chemical Process Research*; Abdel-Magid, A. F., Ed.; ACS Symposium Series 870; American Chemical Society: Washington, DC, 2004, pp 181-197.
15. A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo. de Garavilla, L.; Greco, M. N.; Sukumar, N.; Chen, Z.-W.; Pineda, A. O.; Mathews, F. S.; Di Cera, E.; Giardino, E. C.; Wells, G. I.; Haertlein, B. J.; Kauffman, J. A.; Corcoran, T. W.; Derian, C. K.; Eckardt, A. J.; Andrade-Gordon, P.; Damiano, B. P.; Maryanoff, B. E. *J. Biol. Chem.* **2005**, *280*, 18001.
16. Selection of a 2-azabicyclo[2.2.2]octane-based $\alpha_4\beta_1$ integrin antagonist as an inhaled anti-asthmatic agent. Lawson, E. C.; Santulli, R. J.; Dyatkin, A. B.; Ballentine, S. A.; Abraham, W. M.; Rudman, S.; Page, C.; DeGaravilla, L.; Damiano, B. P.; Kinney, W. A.; Maryanoff, B. E. *Bioorg. Med. Chem.* **2006**, *14*, 4208.
17. Adventures in drug discovery: potent agents based on ligands for cell-surface receptors. Maryanoff, B. E. *Acc. Chem. Res.* **2006**, *39*, 831.
18. Discovery of potent, orally active, nonpeptide inhibitors of human mast cell chymase. Greco, M. N.; Hawkins, M. J.; Powell, E. T.; Almond, Jr. H. R.; de Garavilla, L.; Hall, J.; Minor, L. K.; Wang, Y.; Corcoran, T. W.; Di Cera, E.; Cantwell, A. M.; Savvides, S. N.; Damiano, B. P.; Maryanoff, B. E. *J. Med. Chem.* **2007**, *49*, 1727.
19. Novel bis-(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3. Zhang, H.-C.; Bonaga, L. V. R.; Ye, H.; Derian, C. K.; Damiano, B. P.; Maryanoff, B. E. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 2863.
20. Pyridine-containing macrocycles via cobalt-mediated [2 + 2 + 2] cycloadditions of α,ω -bis-alkynes. Maryanoff, B. E.; Zhang, H.-C. *Arkivoc* **2007**, (xii), 7.
21. Degradation of rapamycin and its ring-opened isomer: role of base catalysis. Il'ichev, Y. V.; Alquier, L.; Maryanoff, C. A. *Arkivoc* **2007**, (xii), 110.
22. Collagen-related peptides: self-assembly of short, single strands into a functional biomaterial of micrometer scale. Cejas, M. A.; Kinney, W. A.; Chen, C.; Leo, G. C.; Tounge, B. A.; Vinter, J. G.; Joshi, P. P.; Maryanoff, B. E. *J. Am. Chem. Soc.* **2007**, *129*, 2202.

23. Potent, nonpeptide inhibitors of human mast cell tryptase. Synthesis and biological evaluation of novel spirocyclic piperidine amide derivatives. Costanzo, M. J.; Yabut, S. C.; Zhang, H.-C.; White, K. B.; de Garavilla, L.; Wang, Y.; Minor, L. K.; Tounge, B. A.; Barnakov, A. N.; Lewandowski, F.; Milligan, C.; Spurlino, J. C.; Abraham, W. M.; Boswell-Smith, V.; Page, C. P.; Maryanoff, B. E. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 2114.
24. Thrombogenic collagen-mimetic peptides: self-assembly of triple helix-based fibrils driven by hydrophobic interactions. Cejas, M. A.; Kinney, W. A.; Chen, C.; Vinter, J. G.; Almond, Jr. H. R.; Maryanoff, C. A.; Balss, K.; Breslav, M.; Lacy, E.; Maryanoff, B. E. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 8525.
25. Multivariate analysis applied to the study of spatial distributions found in drug-eluting stent coatings by confocal raman microscopy. Balss, K. M.; Long, F. H.; Veselov, V.; Orana, A.; Akerman-Revis, E.; Papandreou, G.; Maryanoff, C. A. *Anal. Chem.* **2008**, *80*, 4853.
26. Adhesion and interfacial fracture toughness between hard and soft materials pertaining to medical devices. Rahbar, N.; Wolf, K.; Orana, A.; Fennimore, R.; Zong, Z.; Meng, J.; Papandreou, G.; Maryanoff, C.; Soboyejo, W. *J. Appl. Phys.* **2008**, *104*, 103533/1.
27. Pharmaceutical "Gold" from neurostabilizing agents: topiramate and successor molecules. B. E. Maryanoff, *J. Med. Chem.* **2009**, *52*, 3431.
28. Sugar sulfamates for seizure control: discovery and development of topiramate, a structurally unique antiepileptic drug. Maryanoff, B. E. *Curr. Top. Med. Chem.* **2009**, *9*, 1048.
29. Urotensin-II receptor modulators as potential drugs. Maryanoff, B. E.; Kinney, W. A. *J. Med. Chem.* **2010**, *53*, 2695.